Inovio Pharmaceuticals Inc vs Las Vegas Sands Corp. — how do they compare? Inovio Pharmaceuticals Inc trades at $1.08 (market cap $89.27M), while Las Vegas Sands Corp. trades at $45.87 (market cap $30.36B). The key difference: Las Vegas Sands Corp. is far larger — about 340.1× Inovio Pharmaceuticals Inc's market cap, and Las Vegas Sands Corp. pays a 2.4% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | LVS | |
|---|---|---|
Market Cap | $89.27M | $30.36B |
Sector | Health | Consumer Cyclical |
52-Week High | $2.87 | $69.49 |
52-Week Low | $1.05 | $44.78 |
Enterprise Value | $60.28M | $42.75B |
Dividend Yield | — | 2.4% |
Trailing returns across standard periods
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →